Webinar : Amitraz resistance in varroa: separating lab findings from field reality

A varroa mite mutation linked to amitraz resistance has been identified in Australia. Before you change your entire treatment plan — or worse, do nothing — watch this webinar for an honest conversation about what the science actually says, and what it means for your hives.

Amitraz is one of the most widely used varroa treatments in the world. Its effectiveness depends on how you use it — and for how long beekeepers as a whole keep using it correctly. Recent findings in Australia have raised legitimate questions. But between a lab mutation and treatment failure in your apiary, there’s a lot of ground that rarely gets covered clearly.

Dr John Mackay will walk through what the resistance data actually shows — and what it doesn’t. Rémi Padé, Bee R&D Manager at Véto-pharma, brings over 30 years of experience managing varroa with amitraz across France and Europe, where resistance pressure has been building for decades. And beekeepers from North America will share how they’ve built Varroa Integrated Management strategies that hold up in the real world, not just on paper.

WHAT WE COVER

• What the Australian resistance findings actually mean — and what they don’t

• How resistance develops in the field, and why lab results don’t always translate directly

• Where amitraz still fits in a sound varroa management plan

• Active ingredient rotation: when it matters, and how to do it without undermining your mite management strategy

• How North American beekeepers have structured their Varroa management approach — and what Australia can learn from it

• Monitoring and timing: the variables that make or break any treatment protocol